Table 2.
Top 10 best-selling monoclonal antibody drugs in 2018
| No. | Drug | Indication (1st US FDA Approval Year) | Company | 2018 Revenue (USD) |
|---|---|---|---|---|
| 1 |
Adalimumab (Humira) |
Rheumatoid arthritis (2002) Psoriatic arthritis (2005) Ankylosing spondylitis (2006) Juvenile Idiopathic Arthitis (2008) Psoriasis (2008) Crohn’s disease (2010) Ulcerative colitis (2012) Hidradenitis suppurativa (2015) Uveitis (2018) |
AbbVie | $19.9 bn |
| 2 |
Nivolumab (Opdivo) |
Melanoma (2015) Non-small cell lung cancer (2015) Renal cell carcinoma (2015) Head and neck squamous cell (2016) |
Bristol-Myers Squibb | $7.6 bn |
| 3 |
Pembrolizumab (Keytruda) |
Melanoma (2014) Head and neck cancer (2016) Non-small cell lung caccer (2015) Lymphoma (2018) Cervical cancer (2018) Microsatellite instability-high cancer (2018) |
Merck & Co | $7.2 bn |
| 4 |
Trastuzumab (Herceptin) |
Breast cancer (1998) Gastric cancer (2010) |
Roche | $7.0 bn |
| 5 |
Bevacizumab (Avastin) |
Colorectal cancer (2004) Non-small cell lung caccer (2006) Breast ERB2 negative cancer (2008) Renal cell carcinoma (2009) Glioblastoma (2011) |
Roche | $6.8 bn |
| 6 |
Rituximab, (Rituxan) |
Non-Hodgkin’s lymphoma (1997) Chronic lymphocytic leukemia (2010) Rheumatoid arthritis (2006) Pemphigus vulgaris (2018) |
Roche | $6.8 bn |
| 7 |
Infliximab (Remicade) |
Crohn’s Disease (1998) Rheumatoid arthritis (1999) Ankylosing spondylitis (2004) Ulcerative colitis (2005) Psoriatic arthritis (2005) Psoriasis (2006) |
Johnson & Johnson | $5.9 bn |
| 8 |
Ustekinumab (Stelara) |
Psoriasis (2009) Psoriatic arthritis (2013) Crohn’s Disease (2016) |
Johnson & Johnson | $5.2 bn |
| 9 |
Eculizumab (Soliris) |
Paroxysmal nocturnal hemoglobinuria (2007) Atypical hemolytic uremic syndrome (2011) Generalized myasthenia gravis (2017) Neuromyelitis optica spectrum disorder (2019) |
Alexion | $3.6 bn |
| 10 |
Omalizumab (Xolair) |
Asthma (2003) Chronic idiopathic urticaria (2014) |
Roche | $3.0 bn |
bn, billion